Table 1 Baseline analysis of the 4 included papers
Study | Year | Region | Study design | Study period | Diagnostic standard | Study Group | Gender (n) | Age (mean [SD], month) | Cut-off value | TP (n) | FP (n) | FN (n) | TN (n) | |
Male | Female | |||||||||||||
Li Gang [16] | 2020 | Sichuan, China | RCS | 2013.06-2019.08 | AHA | IVIG response | 486 | 312 | 23.0 (12.0–38.0) | 3.14 | 111 | 198 | 48 | 600 |
IVIG-resistance | 84 | 75 | 26.0 (13.0–40.0) | |||||||||||
Liu Xiaoliang [17] | 2021 | Sichuan, China | PCS | 2015.03-2019.06 | AHA | IVIG response | 271 | 200 | 24.0 (13.0–42.0) | 2.07 | 48 | 211 | 31 | 260 |
IVIG-resistance | 43 | 36 | 28.0 (14.0–54.0) | |||||||||||
Wang Zhenquan [18] | 2021 | Zhejiang, China | RCS | 2021.01-2022.12 | AHA | IVIG response | 653 | 17.4 | 2.20 | 36 | 254 | 25 | 399 | |
IVIG-resistance | 61 | 24.4 | ||||||||||||
Wu Hang [19] | 2023 | Zhejiang, China | PCS | 2018.01-2019.12 | AHA | IVIG response | 47 | 48 | 28.0(14.0–51.0) | 2.89 | 5 | 12 | 5 | 83 |
IVIG-resistance | 5 | 5 | 31.0 (14.0–71.0) | |||||||||||